QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Presents Initial Data from Bria-IMT Combination Study at Major Breast Cancer Conference
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatment options for cancer, this morning announced the presentation of initial safety data from the combination study of its lead candidate, Bria-IMT, with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)] and confirmation of positive proof of concept data on Bria-IMT for advanced breast cancer at the 2018 San Antonio Breast Cancer Symposium. “I am very excited about our data continuing to show robust biological activity of Bria-IMT™ in advanced breast cancer,” Dr. Bill Williams, president and CEO of BriaCell, stated in the news release.…